Pre-made Obrindatamab biosimilar ( Bispecific scFv with Domain Crossover, anti-CD276;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-386
Anti-CD276;CD3E therapeutic antibody (Pre-made Obrindatamab biosimilar,Bispecific scFv with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Obrindatamab (formerly orlotamab) was a Fc-bearing humanised bispecific dual-affinity re-targeting (DART) protein, that was being developed by MacroGenics for the treatment of solid tumours.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD276;CD3E therapeutic antibody (Pre-made Obrindatamab biosimilar,Bispecific scFv with Domain Crossover)|
|Format||Bispecific scFv with Domain Crossover|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Discontinued||Advanced or Metastatic solid tumours|